ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases

WESTON, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published data further substantiating the potential of Inflammasome ASC Inhibitor IC 100 as a disease-modifying treatment for PD. There is a tremendous unmet medical need for therapeutic options that slow the progression of PD, which affects over 10 million people globally. Current therapies, which address symptoms, but not the underlying disease pathology, generated $6.6 billion globally in 2024, and are projected to generate $13.3 billion by 2034 (Precedence Research).

Read more at globenewswire.com